Antibody Information

General Information of This Antibody
Antibody ID
ANI0BLMDT
Antibody Name
BAY-865
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
USTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HER2 KSP-ADC 2.1 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.02 nM
Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
HER2 KSP-ADC 2.2 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.07 nM
Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
HER2 KSP-ADC 1.3 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.07 nM
Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
HER2 KSP-ADC 1.4 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 nM
Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
HER2 KSP-ADC 1.1 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.70 nM
Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
HER2 KSP-ADC 1.2 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.80 nM
Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
References
Ref 1 Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. Angew Chem Int Ed Engl. 2018 Nov 12;57(46):15243-15247. doi: 10.1002/anie.201807619. Epub 2018 Oct 15.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.